Simplify Logo

Full-Time

Portfolio Marketing Manager

Posted on 5/28/2024

Revance

Revance

501-1,000 employees

Develops neuromodulator treatments for frown lines

Compensation Overview

$102.5k - $140.9kAnnually

+ 401k match + ESPP program + Tuition Reimbursement + Wellness Discounts

Mid, Senior

Nashville, TN, USA + 1 more

Category
Brand & Creative Marketing
General Marketing
Growth Marketing
Growth & Marketing
Required Skills
Marketing
Requirements
  • Doctorate degree
  • Master's degree
  • Bachelor's degree
  • Associate's degree
  • High school diploma / GED
  • 1 year of managerial experience
Responsibilities
  • Represent Marketing on cross-departmental teams to develop customer engagement, retention and loyalty initiatives.
  • Assist in the development of go-to-market plans.
  • Manage vendor and third-party relationships as necessary.
  • Own go-to-market marketing tasks to help drive customer engagement, retention and loyalty.
  • Execute research, testing and exploratory initiatives to ensure programs deliver value to customers, driving continued engagement and retention, and growing customer lifetime value.
  • Support pilot programs by capturing customer feedback, supporting customer testing, preparing value analyses, and assisting in proposed go-forward recommendations for scaling in-market.
  • Monitor program performance metrics and KPIs (key performance indicators).
  • Support market and competitor research.
  • Support additional portfolio initiatives as needed for the business.

Revance specializes in a neuromodulator therapeutics pipeline featuring DaxibotulinumtoxinA for Injection, utilizing acetylcholine release inhibition and neuromuscular blocking agents to temporarily improve moderate to severe glabellar lines in adults. The product uses peptide-powered technology to provide long-lasting treatment for frown lines.

Company Stage

IPO

Total Funding

$1.8B

Headquarters

Nashville, Tennessee

Founded

1999

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

-6%

2 year growth

17%
INACTIVE